Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT00673023 Completed - Metabolic Syndrome Clinical Trials

Study the Role of Genetic Variation in the Determining Lipid Profile Response to Dietary Change

Start date: October 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether plasma lipoproteins and lipid responsiveness to a dietary modification is influenced by CETP gene polymorphism.

NCT ID: NCT00666848 Completed - Hypertension Clinical Trials

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

Start date: March 2008
Phase: Phase 4
Study type: Interventional

This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.

NCT ID: NCT00666029 Completed - Metabolic Syndrome Clinical Trials

Implications for Treatment of the Metabolic Syndrome

Start date: February 2006
Phase: Phase 2
Study type: Interventional

To characterize features of metabolic syndrome in volunteers. To undertake a randomised trial to determine whether treatment with a statin improves muscle microvascular blood flow.

NCT ID: NCT00664742 Completed - Metabolic Syndrome Clinical Trials

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

Start date: September 2006
Phase: Phase 4
Study type: Interventional

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome

NCT ID: NCT00664729 Completed - Metabolic Syndrome Clinical Trials

Diet, Exercise, Metabolism, and Obesity in Older Women

DEMO
Start date: November 2002
Phase: N/A
Study type: Interventional

Reductions in fat oxidation and resting metabolic rate (RMR) are associated with normal aging and are accelerated with menopause. As a result, postmenopausal women have an increased risk of abdominal obesity and ultimately the metabolic complications that lead to the insulin resistance syndrome and its associated risks (hyperlipidemia, type 2 diabetes, and coronary heart disease). Thus, there is a need to determine the most successful treatment to reduce visceral obesity in postmenopausal women. The purpose of this study is to determine if dietary-induced weight loss alone and/or weight loss combined with exercise at low and high- intensities differentially affect the reduction in visceral adipose tissue in postmenopausal women with abdominal obesity.

NCT ID: NCT00659828 Completed - Obesity Clinical Trials

Effects of Leptin Replacement in Children

Start date: June 2005
Phase: Phase 2
Study type: Interventional

To assess the endocrine and immune effects of leptin replacement in leptin-deficient children, from a consanguineous family. The hypothesis is that leptin replacement will have significant effects on endocrine function.

NCT ID: NCT00659321 Completed - Metabolic Syndrome Clinical Trials

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation and the risk of atherosclerosis.

NCT ID: NCT00657605 Completed - Obesity Clinical Trials

Effects of Human Leptin Replacement

Start date: June 2001
Phase: Phase 2
Study type: Interventional

This study will test the hypothesis that leptin contributes to the regulation of the dynamics of human endocrine function.

NCT ID: NCT00655902 Completed - Type 2 Diabetes Clinical Trials

Copenhagen Obesity Risk Assessment Study

COBRA
Start date: April 2008
Phase: N/A
Study type: Interventional

The aim of the present study is to assess the effect of a high intake of industrially produced trans fatty acids for 16 weeks on abdominal obesity and risk markers of type 2 diabetes and heart disease in healthy, moderately overweight, postmenopausal women.

NCT ID: NCT00654485 Completed - Metabolic Syndrome Clinical Trials

COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects

Start date: May 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of treatment with rosuvastatin with atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in subjects with metabolic syndrome.